Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Thyroid Cancer
Researchers develop signature for scoring thyroid cancers
By
LabPulse.com staff writers
A team led by researchers at Vanderbilt University Medical Center has developed a signature for thyroid cancer aggressiveness that incorporates immune and other microenvironment features through multiomic analyses.
September 20, 2023
Veracyte announces clinical practice data for thyroid cancer classifier
By
LabPulse.com staff writers
According to Veracyte, data from a meta-analysis of 13 independent studies show that among other findings, its Afirma genomic sequencing classifier can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules.
December 16, 2022
Interpace Biosciences announces data for test to assess indeterminate thyroid nodules
By
LabPulse.com staff writers
The data support both versions of its test platform and a blinded analysis of pairwise miRNA expression profiling demonstrated greater accuracy than its original testing platform, the firm said.
October 21, 2022
Interpace announces validation data for thyroid cancer test
By
LabPulse.com staff writers
The company said the most recent data shows that the addition of microRNA pairwise expression profiling on its ThyraMIRv2 assay provides clinically and statistically superior risk stratification of indeterminate thyroid nodules by the original ThyraMIR assay.
September 1, 2022
Veracyte announces study results for thyroid cancer classifier
By
LabPulse.com staff writers
The results suggest that the firm's RNA sequencing-based medullary thyroid cancer classifier, Afirma, may enable more timely diagnosis of this rare, aggressive form of thyroid cancer, Veracyte said.
July 21, 2022
Eurofins subsidiary launches at-home test for 'forever chemicals'
By
LabPulse.com staff writers
These compounds tend to break down very slowly in both the environment and in people's bodies and exposure to them can cause cancer, thyroid disease, immune suppression, and respiratory disease as well as decrease fertility, Eurofins said. Identifying the presence of these compounds through a blood test is new, according to the firm.
January 23, 2022
Bayer and Veracyte team up on thyroid cancer genomic profiling
By
LabPulse.com staff writers
Per the partnership, thyroid cancer patients will undergo whole-transcriptome sequencing testing with Veracyte's Afirma Xpression Atlas (XA) for underlying mutations, including NTRK gene fusions. The testing identifies 905 DNA variants and 235 RNA fusions in 593 genes on fine needle aspirates taken from thyroid nodules or lymph nodes, the companies explained in a statement.
December 21, 2020
Bayer, Tempus join forces on cancer testing
By
LabPulse.com staff writers
The assay will be available for a subset of patients with metastatic colorectal cancer (mCRC), as well as those with radioactive iodine refractory differentiated metastatic thyroid carcinoma (RAIR thyroid cancers).
December 10, 2020
Bayer, NeoGenomics offer free genomic testing for thyroid, colorectal cancers
By
LabPulse.com staff writers
Under the program, genomic cancer testing for NTRK gene fusions will be available at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). More commonly found in these patients, NTRK fusions have been shown to drive tumor growth and may play a role in disease management, according to the companies.
May 5, 2020
New thyroid test could help patients avoid surgery
By
LabPulse.com staff writers
A group of researchers from the University of Texas at Austin (UT Austin) and other institutions developed a new preoperative metabolic test for thyroid cancer that is faster and more accurate than current diagnostic tests, according to a statement released by the university. The technique uses mass spectrometry imaging to identify metabolites produced by cancer cells.
October 7, 2019
Veracyte validates Afirma XA in thyroid cancer
By
LabPulse.com staff writers
Veracyte describes Afirma XA as an RNA whole transcriptome sequencing test designed to detect DNA variants and RNA fusion partners in 511 genes associated with thyroid cancer. Testing is performed as a follow-up for suspicious nodules detected on the company's Afirma Genomic Sequencing Classifier (GSC). Both tests are conducted on fine-needle aspiration (FNA) samples of nodules, and only one sample is needed per patient. The study results were reported by lead author Dr. Trevor Angell, an associate medical director of thyroid cancer at the University of Southern California, and colleagues.
September 12, 2019
Thermo Fisher seals companion test deal with Lilly
By
LabPulse.com staff writers
LOXO-292 is an investigational drug in phase I/II development for cancers with rearranged during transfection (RET) alterations. An estimated 2% of non-small cell lung cancers and 60% of medullary thyroid cancers have RET alterations.
September 8, 2019
Page 1 of 2
Next Page